Χώρα: Ισραήλ
Γλώσσα: Αγγλικά
Πηγή: Ministry of Health
GLUCOSE AS MONOHYDRATE; SODIUM CHLORIDE
TEVA ISRAEL LTD
B05BB02
SOLUTION FOR INFUSION
GLUCOSE AS MONOHYDRATE 5 %W/V; SODIUM CHLORIDE 0.45 %W/V
I.V
Required
BAXTER HEALTHCARE LTD. U.K.
ELECTROLYTES WITH CARBOHYDRATES
Sodium Chloride 0.45 % And Glucose 5 % Soution For Infusion Baxter is indicated to provide electrolytes and calories and as a source of water for hydration
2020-04-02
SA-30-02-449 1. NAME OF THE MEDICINAL PRODUCT Sodium Chloride 0.45 % and Glucose 5.0 % Solution for Infusion Baxter 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium Chloride: 4.5 g/l (0.45 % w/v) Glucose (as monohydrate): 50.00 g/l (5.0 % w/v) Each ml contains 50 mg glucose (as monohydrate) and 4.5 mg sodium chloride. mmol/l: Na+: 77 Cl-:77 mEq/l: Na+: 77 Cl-:77 Nutritional value: approximately 840 kJ/l (or 200 kcal/l) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion. Clear solution, free from visible particles. Osmolarity 432 mOsm/l (approx) pH: 3.5 to 6.5 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Sodium Chloride 0.45 % And Glucose 5 % Solution for Infusion Baxter is indicated to provide electrolytes and calories and as a source of water for hydration. 4.2 Posology and method of administration As directed by a physician. Dosage is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The dosage and constant infusion rate of intravenous Sodium Chloride 0.45 % and Glucose 5.0 % Solution for Infusion Baxter must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. The infusion rate and volume depend on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy. Precautions to be taken before manipulating or administering the product Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless solution is clear, and seal is intact. Administer immediately following the insertion of infusion set. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product. All injections in plastic containers are intended for i Διαβάστε το πλήρες έγγραφο